Literature DB >> 30426122

The effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials.

Reza Tabrizi1, Omid Reza Tamtaji, Kamran B Lankarani, Naghmeh Mirhosseini, Maryam Akbari, Ehsan Dadgostar, Payam Peymani, Zatollah Asemi.   

Abstract

There are several current trials investigating the effect of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome (MetS); however, their findings are controversial. This systematic review and meta-analysis of randomized controlled trials (RCTs) were conducted to summarize the existing evidence and collectively determine the effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with MetS and related disorders. Two authors independently searched electronic databases, including MEDLINE, EMBASE, Cochrane Library, and Web of Science databases, until May 2018 in order to find relevant RCTs. The quality of the selected RCTs was evaluated using the Cochrane Collaboration risk of bias tool. Cochran's Q test and I-square (I2) statistic were used to determine whether heterogeneity exists across included trials. Standardized mean difference (SMD) and 95% CI between two intervention groups were used to determine pooled effect sizes. Out of 317 potential citations selected based on keywords, 24 RCTs met the inclusion criteria and were eligible for the current meta-analysis. The pooled results obtained by using the random-effects model showed that resveratrol supplementation significantly decreased C-reactive protein (CRP) (SMD = -0.55; 95% CI, -0.84, -0.26; P < 0.001; I2: 84.0) and tumor necrosis factor-α (TNF-α) (SMD = -0.68; 95% CI, -1.08, -0.28; P = 0.001; I2: 81.3) concentrations among patients with MetS and related disorders. Interleukin 6 (IL-6) (SMD = 0.05; 95% CI, -0.31, 0.41; P = 0.79; I2: 85.0) and superoxide dismutase (SOD) (SMD = 0.21; 95% CI, -3.16, 3.59; P = 0.90; I2: 97.7) concentrations did not significantly change following resveratrol supplementation. Resveratrol supplementation showed a promising lowering effect on some of the inflammatory markers among patients with MetS and related disorders. Additional prospective studies regarding the effect of resveratrol supplementation on biomarkers of inflammation and oxidative stress by using higher doses of resveratrol and longer duration of supplementation are necessary.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30426122     DOI: 10.1039/c8fo01259h

Source DB:  PubMed          Journal:  Food Funct        ISSN: 2042-6496            Impact factor:   5.396


  10 in total

Review 1.  Pharmacological basis and new insights of resveratrol action in the cardiovascular system.

Authors:  Chak Kwong Cheng; Jiang-Yun Luo; Chi Wai Lau; Zhen-Yu Chen; Xiao Yu Tian; Yu Huang
Journal:  Br J Pharmacol       Date:  2019-12-08       Impact factor: 8.739

Review 2.  The Potential of Resveratrol to Act as a Caloric Restriction Mimetic Appears to Be Limited: Insights from Studies in Mice.

Authors:  Kathrin Pallauf; Ilka Günther; Gianna Kühn; Dawn Chin; Sonia de Pascual-Teresa; Gerald Rimbach
Journal:  Adv Nutr       Date:  2021-06-01       Impact factor: 8.701

Review 3.  The Effects of Resveratrol in the Treatment of Metabolic Syndrome.

Authors:  Chih-Yao Hou; You-Lin Tain; Hong-Ren Yu; Li-Tung Huang
Journal:  Int J Mol Sci       Date:  2019-01-28       Impact factor: 5.923

4.  The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Maryam Akbari; Omid Reza Tamtaji; Kamran B Lankarani; Reza Tabrizi; Ehsan Dadgostar; Neda Haghighat; Fariba Kolahdooz; Amir Ghaderi; Mohammad Ali Mansournia; Zatollah Asemi
Journal:  Lipids Health Dis       Date:  2020-02-17       Impact factor: 3.876

Review 5.  Relation of Fruits and Vegetables with Major Cardiometabolic Risk Factors, Markers of Oxidation, and Inflammation.

Authors:  Maria Lapuente; Ramon Estruch; Mana Shahbaz; Rosa Casas
Journal:  Nutrients       Date:  2019-10-06       Impact factor: 5.717

6.  The Cholinergic Drug Galantamine Alleviates Oxidative Stress Alongside Anti-inflammatory and Cardio-Metabolic Effects in Subjects With the Metabolic Syndrome in a Randomized Trial.

Authors:  Carine Teles Sangaleti; Keyla Yukari Katayama; Kátia De Angelis; Tércio Lemos de Moraes; Amanda Aparecida Araújo; Heno F Lopes; Cleber Camacho; Luiz Aparecido Bortolotto; Lisete Compagno Michelini; Maria Cláudia Irigoyen; Peder S Olofsson; Douglas P Barnaby; Kevin J Tracey; Valentin A Pavlov; Fernanda Marciano Consolim Colombo
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

7.  A study protocol for a randomized controlled trial of an anti-inflammatory nutritional intervention in patients with fibromyalgia.

Authors:  Ana Rita Silva; Alexandra Bernardo; Maria Fernanda de Mesquita; José Vaz Patto; Pedro Moreira; Maria Leonor Silva; Patrícia Padrão
Journal:  Trials       Date:  2021-03-09       Impact factor: 2.279

8.  The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials.

Authors:  Yuqiong Lu; Xiwen Zhang; Jiafang He; Zhanjing Dai; Penghua Shi; Yun Lu; Feng Chang
Journal:  Inflammopharmacology       Date:  2022-03-29       Impact factor: 5.093

Review 9.  Resveratrol and Markers of Polycystic Ovary Syndrome: a Systematic Review of Animal and Clinical Studies.

Authors:  Sara Shojaei-Zarghani; Maryam Rafraf
Journal:  Reprod Sci       Date:  2021-07-26       Impact factor: 2.924

10.  Resveratrol stereoselectively affected (±)warfarin pharmacokinetics and enhanced the anticoagulation effect.

Authors:  Tse-Yin Huang; Chung-Ping Yu; Yow-Wen Hsieh; Shiuan-Pey Lin; Yu-Chi Hou
Journal:  Sci Rep       Date:  2020-09-28       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.